factor receptor ␤ (PDGFR␤), and fibroblast growth factor receptor-1 (FGFR-1); and no detectable activity against other protein tyrosine kinases such as epidermal growth factor receptor (EGFR), Src, and hepatocyte growth factor receptor. In cellular assays, the selectivity for SU10944 to inhibit VEGFR is maintained compared with other tyrosine kinases (IC 50 for SCFR of 1.6 Ϯ 0.3 M, for PDGFR␤ of 30.6 Ϯ 13.3 M, for FGFR-1 of Ͼ50 M, and for EGFR of Ͼ50 M). Upon oral administration, SU10944 gave a clear dose response in the corneal micropocket model with an ED 50 value for inhibition of neovascularization of ϳ30 mg/kg and a maximum inhibition of 95% at 300 mg/kg. Similarly, upon oral administration in the Miles assay, SU10944 potently inhibited VEGF-induced vascular permeability. Our data indicate that small molecule inhibitors of VEGFR signaling have the potential to ameliorate VEGFinduced neovascularization as well as vascular permeability.
In diabetic retinopathy (DR) and exudative age-related macular degeneration (AMD), vascular endothelial growth factor (VEGF) is a driver of both the neovascularization and retinal vascular permeability, which underlie the loss of visual acuity. The temporal and spatial expression patterns of VEGF in these diseases implicate VEGF in ocular neovascularization. VEGF expression levels and activity are elevated in vitreous samples from diabetic patients with active proliferative retinopathy, compared with individuals with nonproliferative diabetic retinopathy, quiescent proliferative retinopathy, nondiabetic individuals, or individuals with nonischemic ocular disease (Adamis et al., 1994; Aiello et al., 1994) . The levels of VEGF are positively correlated to the clinically observed degree and stage of retinal neovascularization (Aiello et al., 1994) . In AMD, VEGF is expressed in choroidal neovascular membranes (Frank et al., 1996) .
As with ocular neovascularization, elevated levels of VEGF are associated clinically with ocular edema (Vinores et al., 1995; Funatsu et al., 2002) . In preclinical models, VEGF is likewise associated with changes in vascular integrity. Increases in ocular VEGF in diabetic animals correlate with elevated vascular permeability, before observable retinal proliferative changes (Sone et al., 1997; Gilbert et al., 1998) . Local delivery of VEGF by intravitreal implants result in significant increases in retinal permeability by day 3, whereas retinal neovascularization is observed only after 14 days (Alikacem et al., 2000) . A similar breakdown of the blood-retinal barrier occurs in primates administered VEGF by intravitreal implant (Ozaki et al., 1997) .
Intervention in VEGF signaling, either by decreasing local concentrations of ligand with antisense oligodeoxynucleotides (Robinson et al., 1996) or soluble chimeric receptors (Aiello et al., 1995) , or by inhibiting receptor signaling by small molecules (Ozaki et al., 2000) , decreases ocular neovascularization, thus confirming the central role of VEGF in this process. Neovascularization in DR and AMD may differ significantly from angiogenesis in other pathological contexts such as tumor angiogenesis where multiple targets have been implicated, including PDGF, FGF, and IL-8 (Laird et al., 2000; Rofstad and Halsor, 2000; Shaheen et al., 2001) . Current data strongly suggest that in diabetic retinopathy and exudative age-related macular degeneration, VEGF is the key driver. In a preclinical model of diabetic retinopathy, hypoxia-driven retinal neovascularization, VEGF inhibitors are efficacious but PDGFR inhibitors are not (Ozaki et al., 2000) . Similarly in a model of AMD, injury-induced choroidal neovascularization, a VEGF inhibitor decreases choroidal neovascularization ϳ85%, but administration of a PDGF inhibitor does not decrease choroidal neovascularization (Kwak et al., 2000) . The contribution of FGF to neovascularization is less well understood. Although bFGF is expressed in neovascular membranes from AMD and DR patients (Frank et al., 1996) and intravitreally administered FGF has a synergistic effect with VEGF in producing retinal hemorrhage (Wong et al., 2001) , retinal neovascularization occurs upon hypoxic challenge even in the absence of bFGF (Ozaki et al., 1998) . Moreover, overexpression of bFGF in a transgenic mouse does not produce retinal neovascularization nor increase the degree of neovascularization upon hypoxia (Ozaki et al., 1998) .
Inhibition of PDGF could have deleterious effects, particularly in the context of DR. PDGF seems to play a special role in retinal vasculature. Recent reports suggest that PDGF signaling is important for survival of retinal vasculature, specifically pericytes, under conditions of hypoxic or metabolic stress (Kodama et al., 2001; Hammes et al., 2002) . In vivo, PDGF plays a role in retinal capillary coverage: PDGF-B-deficient mice (PDGFB ϩ/Ϫ) have fewer retinal pericytes and more acellular retinal capillaries than wild-type controls, differences that are more pronounced in diabetic animals. In the hypoxia-induced model of neovascularization, new vessels are twice as prevalent in PDGFB ϩ/Ϫ mice compared with wild-type animals (Hammes et al., 2002) , suggesting that pericyte deficiency renders endothelial cells more susceptible to angiogenesis. Therefore, a potential side effect of PDGF inhibition could be to accelerate the loss of pericytes, which are implicated in the destabilization of blood vessels during the early stages of diabetic retinopathy. Therefore, given the lack of data supporting a role for PDGF in retinal and choroidal neovascularization as well as the risk of increasing pericyte dropout, a VEGF-selective inhibitor is likely the best choice for treatment of retinopathies.
Our goal was to identify and characterize an orally available, selective VEGFR inhibitor, because angiogenesis and increased vascular permeability in DR and exudative AMD are primarily or solely driven by VEGF in these settings. A selective compound should minimize the potential toxicities resulting from the inhibition of additional kinases and be more likely to give a sufficient therapeutic index for the treatment of nonlife-threatening disease.
Materials and Methods
Chemicals. SU10944 was synthesized as described in patent WO00/08202. Its chemical structure is shown in Fig. 1 . Stock solutions of SU10944 were made in dimethyl sulfoxide and stored at Ϫ20°C. Dilutions for assays were made fresh before use.
Kinetic Analysis. The catalytic portion of mouse VEGFR-2 was expressed as a glutathione S-transferase (GST) fusion protein after infection of Spodoptera frugiperda (sf9) cells with engineered baculoviruses by standard methods (King and Possee, 1992) . GST-VEGFR-2 was purified to homogeneity from infected sf9 cell lysates by glutathione-Sepharose chromatography (Smith and Johnson, 1988) . GST-fusion preparations were analyzed by gel electrophoresis and determined to be of high purity, with no detectable breakdown products as determined using protein staining and Western blot analysis for the GST moiety. Protein concentration was determined with the Bio-Rad protein assay reagent kit (Bio-Rad, Hercules, CA) using a standard curve with bovine serum albumin (BSA). For the SU10944 K i determination against VEGFR-2, biochemical kinase reactions were performed as described below (see "Biochemical Assays") in the presence of various ATP and inhibitor concentrations. Rates were expressed as the increase in time-resolved fluorescence resonance energy transfer (TR-FRET) counts per minute of reaction within the linear reaction time. K i values were determined by graphical analysis of the plot of the slopes from the double reciprocal plot versus inhibitor concentration. The final K i value represents the average Ϯ the standard deviation from five independent experiments.
Biochemical Assays. VEGFR-2 and PDGFR␤ TR-FRET autophosphorylation assays were performed as described previously (Moshinsky et al., 2003) . Briefly, 1 nM VEGFR-2 or 5 nM PDGFR␤ was added to a reaction buffer composed of 50 mM HEPES, pH 7.4, 1 mM MnCl 2 , 0.01% BSA, and 1 mM dithiothreitol, containing twice the apparent K m concentration of both ATP and N-terminal biotinylated peptide (KY-tide: KYKKYKKKYKKKKYKYK) in a 50-l total volume. Reactions were allowed to proceed within the linear reaction time then terminated by the addition of 20 l of 90 mM EDTA. Eu-W1024-labeled anti-phosphotyrosine PY20 and Streptavidin: SureLight-Allophycocyanin (PerkinElmer Life Sciences, Foster City, CA) were diluted in Tris-buffered saline containing 0.02% BSA and 0.1% Tween 20 and added to a final concentration of 0.5 and 1.6 nM, respectively. After incubation for at least 10 min, samples were jpet.aspetjournals.org excited at 340 nM, and emissions were read at 665 nM using an LJL Analyst (LJL Biosystems, Sunnyvale, CA). The increase in signal for both assays was determined to be time-dependent with a requirement for ATP, peptide, kinase, and divalent metal cation. FGFR-1 and EGFR autophosphorylation reactions were performed using immunocaptured kinases as described previously (Laird et al., 2000) . The HGFR and VEGFR-1 assays were performed using poly(Glu, Tyr) 4:1 as a substrate as described previously . For the cdk2/cyclin A assay, a scintillation proximity assay method was used (Amersham Pharmaceutical Assays Development Group, 1995) . The SCFR, src, LCK/YES-related Novel tyrosine kinase, and fyn assays were performed in standard TR-FRET format (Kolb et al., 1998 ) using peptide substrates found by screening an internal peptide substrate library. Conditions for compound testing were saturating peptide concentration and an ATP concentration of 2 ⅐ K m .
VEGFR-2 Cell Autophosphorylation Assay. Full-length mouse VEGFR-2 was cloned into the C-terminal 3xFLAG-tag expression vector p3xFLAG-CMV-14 (Sigma-Aldrich, St. Louis, MO). Human embryonic kidney 293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and grown in a 37°C humidified incubator with 5% CO 2 . The construct was transfected into 293T cells using LipofectAMINE2000 (Invitrogen, Carlsbad, CA) under manufacturer's recommendations. After transfection, cells were starved in DMEM containing no serum and 0.1% BSA for 24 h. Cells were then split into 96-well plates and treated with compound in a final concentration of 1% dimethyl sulfoxide for 2 h. Cells were lysed by the addition of HNTG (50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl 2 , 10% glycerol, 1% Triton X-100, 1 mM EGTA), and lysates were transferred to polystyrene 96-well plates that had been precoated with 1 g/well of M2 anti-FLAG monoclonal antibody (Sigma-Aldrich) to capture the 3xFLAG-tagged kinase. Quantitation of phosphorylation was performed by incubating with horseradish peroxidase-labeled anti-phosphotyrosine PY99 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), followed by detection with a 2,2Ј-azino-di-(3-ethylbenzthiazoline sulfonate (6)) diammonium salt color readout.
VEGFR-2 Phosphorylation Detected by Western Blot. NIH/ 3T3 cells stably expressing VEGFR-2 were grown to confluence in DMEM with 10% heat-inactivated calf serum and then incubated in serum-free medium containing different concentrations of SU10944 for 20 h. After stimulation with human recombinant VEGF 165 (R & D Systems, Minneapolis, MN) at 50 ng/ml for 10 min, cells were lysed in lysis buffer containing 50 mM HEPES, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100, 100 mM phenylmethylsulfonyl fluoride, 1 mM sodium vanadate, and 2 g/ml leupeptin and aprotinin. VEGFR-2 protein was isolated with a monoclonal anti-mouse VEGFR-2 antibody made at Sugen, Inc. (South San Francisco, CA), designated L4. Phosphorylation of VEGFR-2 was then analyzed by SDS-polyacrylamide gel electrophoresis followed by Western blotting using biotin-labeled anti-phosphotyrosine PY99 (Santa Cruz Biotechnology, Inc.). Total VEGFR-2 levels were assessed by stripping and reprobing the membrane with anti-VEGFR-2 antibody L4 (Sugen, Inc.).
VEGFR-2 Cellular Functional Assay. The assay is an immunoassay for the quantitative detection of human tissue factor. HUVECs were seeded at 50,000 cell/well in growth medium (endothelial cell basal medium; BioWhittaker, Walkersville, MD) ϩ 10% fetal bovine serum with complete supplements containing human epidermal growth factor (0.5 ml/500 ml), hydrocortisone (0.5 ml/500 ml), gentamicin sulfate amphotericin-B (0.5 ml/500 ml), and bovine brain extract (2 ml/500 ml) (BioWhittaker) in 24-well plates coated with 0.2% gelatin. Cells were grown for 2 days to Ͼ90% confluence and then treated with SU10944 and human recombinant VEGF 165 (R & D Systems) at 50 ng/ml or PMA (phorbol 12-myristate 13-acetate; Sigma-Aldrich) at 10 nM for 4 h; negative control cells received media only. Cells were lysed with HNTG lysis buffer plus EDTA (1:100), protease inhibitor (1:100), and PMSF (1:100) in 125 l/well for 20 min at 4°C. Cell lysates were processed using an IMUBIND tissue factor ELISA kit (American Diagnostica, Greenwich, CT). Briefly, lysates were transferred to 96-well format precoated micro-test strips and incubated at 4°C overnight. The microtest strips were washed four times with wash buffer, and 100 l of biotinylated anti-human tissue factor antibody was added to each well and incubated for 1 h at room temperature. After washing four times, 100 l of diluted streptavidin-horseradish peroxidase-conjugated antibody was added to each well, and incubated for 1 h at room temperature. The wells were washed four times with wash buffer and incubated with 100 l of tetramethyl-benzidine (Sigma-Aldrich) substrate solution for 20 min at room temperature. The reaction was stopped by the additional of 50 l of H 2 SO 4 solution, and absorbance was read on a microplate reader at a wavelength of 450 nm.
Functional Cellular Assays for SCFR, EGFR, PDGFR␤, and FGFR-1. For EGFR, PDGFR␤, and FGFR-1, the functional activity of the receptor was measured by a ligand-induced BrdU incorporation assay in 3T3 cells that endogenously express both FGFR-1 and PDGFR␤ but not EGFR. A single cell line stably transfected with EGFR was used for all assays. Cells seeded in a 96-well plate were made quiescent by serum deprivation for 24 h and then stimulated with FGF2/bFGF (1.5 nM), epidermal growth factor (4 nM), or PDGF (3.8 nM) in the absence or presence of the indicated concentrations of SU10944 for 20 h. BrdU was added for a 2-h labeling period, and the cells were fixed. The amount of BrdU incorporation was determined with an anti-BrdU-peroxidase-conjugated antibody using an ELISA kit (Roche Diagnostics, Indianapolis, IN). Cell viability after exposure to compounds in the assay format was assessed by substituting the addition of BrdU with resazurin (1 mg/ml) at 1:100 after the 20-h incubation. After a 3-h incubation, the absorbance of the samples are measured at 630 nm in "dual wavelength" mode with a filter reading at 450 nm, as a reference wavelength, on a Dynatech ELISA plate reader. Compound was added to wells in the dilutions used to determine IC 50 values, including a negative control in which all components were included except for cells and a positive control in which all components except compound were added. The resazurin assay is based upon the conversion of the dark blue resazurin dye to a pink dye in proportion to the metabolic activity of the cells (O'Brien et al., 2000) . For each IC 50 value, the standard deviation is reported.
The functional activity of SCFR was assessed using a SCF-dependent cell proliferation/survival assay. MO7e cells were grown and expanded in RPMI 1640 medium with 10% fetal bovine serum in the presence of IL-3 (10 ng/ml) and granulocyte-macrophage colonystimulating factor (10 ng/ml). After counting, cells were pelleted by centrifugation and washed twice with PBS. Cells were resuspended in medium containing either IL-3 or SCF (100 ng/m) and aliquoted into 96-well plates at 50,000 cells/well along with varying concentrations of SU10944. After incubation for 3 d at 37°C in a humidified incubator with 5% CO 2 , live cells were quantified by their ability to metabolize resazurin as described above.
Corneal Angiogenesis Model. An intrastromal pocket was surgically created in one or both corneas of each anesthetized SpragueDawley female rat. A slow release hydron/sucralfate pellet containing 150 ng of human recombinant VEGF 165 (PeproTech, Rocky Hill, NJ) was inserted into the pocket as described previously (Kenyon et al., 1996) , the pocket closed to self-seal, and the rats given analgesia and topical antibiotic ointment applied once to the eye. The rats recovered from anesthesia on a warming pad and were returned to their cages. SU10944 was administered daily by gavage in a 1.0-ml suspension of 0.5% methylcellulose (Sigma-Aldrich), 0.025% Tween 20 (Sigma-Aldrich) to four to six rats per dose group beginning the day before implant, and continuing the length of the study. Four days after surgery, the corneas of the reanesthetized rats were examined under a slit lamp microscope and the neovascular response was quantified by measuring the average new vessel length (VL), the corneal radius (r ϭ 2.6 mm), and the contiguous circumferential zone (CH ϭ clock hours where 1 CH is 30°), and applied to the formula area (in square millimeters) ϭ (CH/12) ϫ 3.14(r 2 Ϫ (r Ϫ VL) 2 ). The rats were then immediately euthanized. Eyes from rats that developed infection as a result of the surgery were not included in the study. Six to eight eyes were included per dosing group. The neovascular areas of the vehicle and 250-mg/kg dosed rat corneas were dissected from the eye, flat mounted, and photographed at 4ϫ with a digital camera mounted on a microscope. Rat corneas implanted with pellets containing no growth factor (placebo pellets) generated no new blood vessel growth (Leahy et al., 2002) . All animal treatment protocols were reviewed by and were in compliance with Pharmacia's Institutional Animal Care and Use Committee. Miles Assay for Vascular Permeability. The Miles assay for vascular permeability (Miles and Miles, 1952 ) was adapted to athymic mice as follows. Mice were given a single oral dose of SU10944 or vehicle alone. Simultaneously or at designated later time points, 100 l of 0.5% Evan's blue dye (Sigma-Aldrich) in PBS was administered intravenously via the tail vein. One hour later, mice were injected intradermally (in duplicate sites on their backs) with 400 ng of VEGF (human recombinant VEGF 165 ; R & D Systems) dissolved in 20 l of PBS or (in adjacent duplicate sites) with PBS alone. After an additional 30 min, VEGF-dependent dye leakage from the vasculature into skin was assessed visually and scored semiquantitatively (100, 50, or 0% inhibition for each spot). Two spots per animal allowed each animal to be scored as representing 100, 75, 50, 25, or 0% inhibition. Low-level background effects from time-matched vehicletreated groups were subtracted out.
Determination of SU10944 Plasma Levels. Plasma samples (100 l), SU10944 standard or quality control samples in mouse blank plasma were mixed with acetonitrile (300 l) containing DLpropranolol hydrochloride (internal standard) in a 96-well polypropylene plate (Orochem Technology, Westmont, IL). The plate was mixed by vortex for 1 min and the samples were centrifuged for 10 min at 4000 rpm. Ten microliters of the supernatant was injected onto the liquid chromatograph tandem mass spectrometry system where separation occurred on a BDS HYPERSIL C 18 (5 m, 100 ϫ 4.6 mm) reverse-phase HPLC column (Keystone Scientific, Foster City, CA). The amount of SU10944 and the internal standard in each mouse plasma sample was quantified based on standard curves generated using known amounts of compound ranged from 5 to 10,000 ng/ml. Standard curve samples and quality control samples of SU010944 were prepared by spiking 10 l of stock standard solutions with 90 l of blank plasma.
Results
We identified SU10944 (Fig. 1) as a potent inhibitor of VEGFR as part of our efforts to synthesize and characterize indolin-2-ones as inhibitors of class III receptor tyrosine kinases (Yarden and Ullrich, 1988) . Previous structure-activity relationship studies revealed that modifications on the indolin-2-one core could generate compounds with different kinase selectivity profiles (Sun et al., 1998 (Sun et al., , 1999 . Modifications of the core have also been found to have a dramatic impact on the pharmaceutical properties of the compounds in terms of solubility, metabolic stability, permeability, plasma protein binding, and pharmacokinetic properties.
After the identification of SU10944 as an inhibitor of VEGFR-2 in biochemical assays (IC 50 of 96 Ϯ 20 nM), we went on to further assess the biochemical activity of the compound against other kinases, as well as its potential to act as a competitor for ATP. SU10944 exhibited competitive inhibition with respect to ATP for VEGFR-2. This is indicated by the fact that the lines from the double reciprocal plot (Fig. 2) converge on the y-axis. The K i value was determined to be 21 Ϯ 5 nM. In a panel of kinase assays, SU10944 potently inhibited VEGFR-2 with an IC 50 of 96 Ϯ 20 nM and exhibited even greater activity against VEGFR-1 with an IC 50 of 6 Ϯ 1 nM (Fig. 3) . It showed some activity against (Table 1 ). The compound is not a pan-kinase inhibitor because no discernible inhibition of more distantly related tyrosine kinases was evident, e.g., EGFR and Src.
We then used a panel of three cell-based assays to determine whether the compound could cross the cellular membrane and inhibit VEGFR-2 within cells. In 293T cells transiently transfected with mouse VEGFR-2, SU10944 exhibited an IC 50 of 227 Ϯ 80 nM for receptor autophosphorylation as measured by ELISA (Fig. 4A) . Similarly, in an assay to assess the functional activity of endogenous VEGFR-2 in HUVECs, tissue factor production stimulated by VEGF was inhibited with an IC 50 value of 102 Ϯ 27 nM (Fig. 4B) . However, SU10944 did not inhibit PMA-stimulated release of tissue factor (Fig. 4B) . Final confirmation that the compound inhibits VEGFR-2 receptor phosphorylation was obtained by Western blot analysis of 3T3 cells engineered to express mouse VEGFR-2 (Fig. 4C) . After cells were pretreated with compound and stimulated with VEGF, VEGFR-2 was immunoprecipitated and then detected on the blot with an antiphosphotyrosine antibody. SU10944 inhibited receptor autophosphorylation confirming the results of the 293 assay in a different cell type and assay formats.
For kinases against which SU10944 was active in biochemical assays, cellular assays were performed to determine whether the activity was maintained in a more physiological setting (Table 2 ). Similar to the observations in the panel of biochemical assays, significantly higher concentrations of compound were required to inhibit a closely related subgroup of family members such as FGFR-1, SCFR, and PDGFR␤ than was required for the inhibition of VEGFR-2 in functional assays. The functional activities of the FGFR-1, PDGFR␤, and EGFR were measured by ligand-induced cell proliferation of 3T3 cells as measured by BrdU incorporation. For SCFR, the activity was measured by the SCF-dependent survival of MO7e cells. SU10944 did not exhibit detectable inhibition of EGFR or FGFR-1 (IC 50 values Ͼ 50 M). Furthermore, SU10944 was not cytotoxic: the LD 50 value was Ͼ50 M for 3T3 cells.
We then assessed the ability of SU10944 to inhibit angiogenesis and vascular permeability in vivo when administered by the oral route. In the rat corneal micropocket model of angiogenesis, a VEGF pellet is implanted in the cornea to stimulate neovascularization. In this model, the compound significantly decreased the angiogenesis, both the number of vascular sprouts as well as the length of the sprouts (Fig. 5) . Fig. 4 . SU10944 inhibits VEGFR-2 receptor phosphorylation and functional activity in cells. a, 293T cells transiently transfected with mouse VEGFR-2 were exposed to varying concentrations of SU10944 and receptor phosphorylation detected by ELISA. Error bars represent standard deviations from n ϭ 3. b, HUVECs were stimulated with either PMA f or VEGF ࡗ. Production of tissue factor was measured by ELISA. Error bars represent standard deviations from duplicate samples. c, 3T3 cells stably transfected with mouse VEGFR-2 were stimulated with VEGF. Anti-mouse VEGFR-2 antibody was used for immunoprecipitation from cellular lysates. Western analysis of immunoprecipated proteins was performed using anti-phosphotyrosine antibody or anti-mouse VEGFR-2 antibody. VEGFR-2 0.096 Ϯ 0.020 EGFR Ͼ20 (n ϭ 16) (n ϭ 4) VEGFR-1 0.006 Ϯ 0.001 Src Ͼ20 (n ϭ 5) (n ϭ 8) FGFR1
1.60 Ϯ 0.87 Lyn Ͼ20 (n ϭ 5) (n ϭ 3) PDGFR␤ 1.00 Ϯ 0.08 Fyn Ͼ20 (n ϭ 4) (n ϭ 5) SCFR 1.58 Ϯ 0.27 Cdk2 Ͼ20 (n ϭ 5) (n ϭ 4) HGFR Ͼ20 (n ϭ 8) 
a Functional activity of SCFR was measured in a survival assay for MO7e cells. b Functional activity was measured by BrdU incorporation in 3T3 cells stably transfected with the receptor.
Moreover, SU10944 gave a clear dose response with an ED 50 of ϳ50 mg/kg for inhibition of neovascularization (Fig. 6 ). To increase potential exposure levels upon oral administration by decreasing dissolution rate limitations of the compound, we prepared an in situ sodium salt of SU10944 and repeated the experiment. The sodium salt decreased the apparent ED 50 value slightly, to approximately 30 mg/kg. In addition, a maximum inhibition of 95% was achieved at the highest dose of 300 mg/kg. Increased exposure upon administration of the sodium salt was confirmed in pharmacokinetic studies (data not shown).
In the Miles assay for vascular permeability (Miles and Miles, 1952) , a visualization dye is administered intravenously, followed by a bolus administration of VEGF by the intradermal route. Leakage of the dye in the skin indicates a local increase in vascular permeability. In this assay, SU10944 inhibited VEGF-induced vascular permeability in a time-and dose-dependent manner (Fig. 7a) . Maximum inhibition was observed at the earliest time point (1 h), with decreasing levels of inhibition over the course of 24 h. At 100 mg/kg, the maximum inhibition of vascular permeability was sustained to 2 h, and a 50% reduction in response was still apparent 24 h postdose. In contrast, at the 30-mg/kg dose maximum inhibition was seen at 1 h and decreased dramatically over 24 h to zero. Plasma concentrations of SU01944 were also determined and correlated with inhibition (Fig. 7b) . Based on the total data set that reflects a range of doses and times postadministration of compound, we conclude that SU10944 plasma exposures of 250 ng/ml (844 nM) result in 50% inhibition of VEGF-mediated vascular permeability in vivo.
Discussion
We have identified and characterized a new small molecule inhibitor of VEGF signaling that inhibits both angiogenesis and vascular permeability when administered orally. The compound, SU10944, is a potent ATP-competitive inhibitor of the kinase activity of purified VEGFR-2 with a K i of 21 Ϯ 5 nM and an IC 50 of 96 Ϯ 20 nM. SU10944 also exhibits potent activity against VEGFR-1, with an IC 50 of 6 Ϯ 1 nM. The compound maintains activity in cellular assays against both the mouse(flk-1) and human (KDR) forms of VEGFR-2. In the cellular assay for inhibition of VEGFR-2 autophosphorylation, the compound exhibited an IC 50 of 227 Ϯ 80 nM, a value in good agreement with the IC 50 value obtained in our HUVEC assay for receptor function (IC 50 of 102 Ϯ 27 nM). In the functional assay, we demonstrated that the inhibition of tissue factor production resulted from inhibition of VEGFR by showing that PMA-stimulated release of tissue factor was not affected by the compound. The HUVEC data suggest that the compound will not only be functionally active against human VEGFR-2 but should be active in endothelial cells that are the target for inhibition of angiogenesis and vascular permeability. We were further able to confirm the nature of the cellular activity of SU10944 by visualizing inhibition of receptor phosphorylation by Western analysis.
From a panel of biochemical and cellular assays, we conclude that SU10944 is a relatively selective inhibitor with a strong preference for VEGFRs. The kinase activity of both VEGFR-1 and VEGFR-2 are potently inhibited by the compound, with low-to mid-nanomolar IC 50 values. Some activity was observed in the biochemical assays, particularly against other members of the class III receptor tyrosine kinases, for example, PDGFR␤ (1000 Ϯ 83 nM) and SCFR (1580 Ϯ 270 nM). SU10944 exhibited little or no activity against the other kinases surveyed, which represent a range of tyrosine kinases as well as some serine/threonine kinases. We limited our cellular assays to those kinases that had shown activity in biochemical assays, plus one more distantly related kinase. Consistent with the biochemical observations, the compound displayed very limited cross-reactivity in the cellular functional assays. The most notable crossreactivity occurred against SCFR (IC 50 of 1600 Ϯ 300 nM); however, compared with VEGFR functional readout (IC 50 of 102 Ϯ 27 nM), there was an 18-fold selectivity. Selectivity at the cellular level was good compared with PDGFR␤ (IC 50 of 30.6 Ϯ 13.3 M), with a ratio of 340ϫ. 5 . SU10944 inhibits VEGF-induced neovascular growth in rat corneas. Four days after VEGF pellet implant, the neovascular area of the rat cornea was measured, dissected from the eye, flat mounted, and photographed at 4ϫ with a digital camera mounted on a microscope. a, representative corneas from rats dosed with vehicle. b, corneas from rats dosed with SU10944 free acid at 250 mg/kg. Fig. 6 . Dose response of sodium salt or free acid SU10944 on VEGFinduced neovascular growth in rat corneas. Four days after VEGF pellet implant, the neovascular area of the rat cornea was measured using a calibrated eyepiece mounted on a slit lamp microscope. Vessel length and the contiguous circumferential angle of neovascularization were noted and used to calculate the area of each cornea that was covered with neovessels. This area was expressed as a percentage of the average vehicle-dosed, VEGF-implanted (control) corneas. Error bars represent S.E.M. for n ϭ 6 to 8 eyes. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.001 in Student's t test compared with vehicle. ࡗ, doses of SU10944 sodium salt administered were 0, 3, 10, 30, and 300 mg/kg/day. f, doses of SU10944 free acid administered were 0, 3, 10, 30, 250, and mg/kg/day.
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Although SU10944 inhibited the kinase activity of purified VEGFR-2 with an IC 50 of 96 Ϯ 20 nM, when the compound was tested in cellular assays the apparent IC 50 value shifted to 227 Ϯ 80 nM in the autophosphorylation assay but was in very close agreement with the functional assay (IC 50 of 102 Ϯ 27 nM). A more notable discrepancy was observed between the IC 50 values for the kinase activity of purified PDGFR␤ (1,000 Ϯ 83 nM) compared with the cellular assay (IC 50 of 30.6 Ϯ 13.3 M). Modest discrepancies between the biochemical and cellular values are not uncommon findings with small molecule enzyme inhibitors because the physical properties of the compounds as well as the assay format become important when translating from biochemical to cellular activity. To inhibit activity of the kinase within a cellular context, the compound must cross the cell membrane and retain activity in the presence of cellular proteins. In addition, differences in assay formats can influence the observed IC 50 values.
In the context of potential treatments for exudative AMD and diabetic retinopathy, a therapeutic molecule should inhibit both neovascularization as well as increased vascular permeability to be maximally effective. In preclinical models, SU10944 potently inhibited both VEGF-induced angiogenesis and vascular permeability after administration by the oral route. In the corneal micropocket model of angiogenesis, we observed a clear dose response with a maximal inhibition of nearly 100%. Compound levels obtained by oral administration clearly achieved sufficient exposure levels to inhibit the functional activity of the receptor. Similarly, in the Miles assay of vascular permeability, a time-and dose-dependent response was observed. The maximum response was nearly 100%, confirming that in a second species and different model, pharmacologically relevant levels of drug were achieved by oral administration.
We note that there is a discrepancy between the in vitro potency of SU10944 (227 Ϯ 80 nM in the autophosphorylation assay, 102 Ϯ 27 nM in the functional assay) and its in vivo activity as measured in the vascular permeability assay (EC 50 cut-off estimated to be 833 nM). Although there can be many reasons for such observed differences in the translation from in vitro to in vivo results, the main source in this case is likely to be high plasma protein binding of the compound. Other compounds in the series have been shown to have high protein binding; our data suggest protein binding of Ͼ98% (data not shown). The unbound concentration of SU10944 in vivo would therefore be roughly 16 nM, a value in better agreement with our in vitro observations.
To develop the compound for potential use in the treatment of human ocular disease, the efficacy of the compound in more relevant disease models, as well as the potential safety of the compound with systemic administration will require careful investigation. The activity of the compound in human retinal endothelial cells and in more physiologically relevant animal models such as retinal vascular permeability in streptozoticininduced rats, hypoxia-driven retinal angiogenesis in mouse neonates, and laser injury-induced choroidal neovascular model of AMD should be determined. In addition, the therapeutic index of such compounds will be essential to establish because of potential mechanism-based toxicities with systemically administered VEGFR inhibitors, particularly in the context of diabetic comorbidities. One area of particular concern is whether VEGFR inhibitors will further impair coronary collateral formation in diabetic patients, in response to myocardial ischemia. Collateral vessel development occurs by the process of arteriogenesis, the expansion of existing arterioles, a process that is differentially regulated from angiogenesis. Monocyte migration into the area of ischemia is a key process in the formation of the collateral vessels. Current evidence suggests that impaired collateral vessel formation in diabetic individuals results from a signaling defect downstream of VEGFR-1 in monocytes (Waltenberger, 2001 ), which normally respond to VEGF-A by increased migration. Because the signaling via VEGFR-1 is already impaired in diabetic patients, it remains to be determined Fig. 7 . SU10944 inhibits VEGF-dependent vascular permeability in athymic mice in a dose-dependent manner. a, the Miles assay was performed as described under Materials and Methods. Each spot was semiquantitatively scored as representing 100, 50, or 0% inhibition; two spots per animal allowed each animal to be scored as representing 100, 75, 50, 25, or 0% inhibition. Values shown are averages (total of six spots, three animals), with any low-level background effects from time-matched vehicle-treated groups subtracted out. Error bars represent S.E. Vascular permeability in animals treated with SU10944 at 100 and 30 mg/kg was significantly inhibited ‫,ء(‬ p Ͻ 0.002; ‫,ءء‬ p Ͻ 0.02 using Student's t test, two-tailed), relative to that seen in animals treated at 3 mg/kg (low, nonefficacious dose). b, comparison of plasma concentration versus percentage of inhibition in individual animals. Based on these data, the median inhibitor plasma concentration associated with 50% inhibition of vascular permeability was 250 ng/ml. at ASPET Journals on July 7, 2017 jpet.aspetjournals.org whether a VEGFR-1 inhibitor would be additive or neutral for collateral formation, or whether a selective VEGFR-2 inhibitor would be preferred for treatment of diabetic retinopathy.
Unlike VEGFR-2, VEGFR-1 has not been implicated directly in mediating VEGF-induced angiogenesis or vascular permeability. However, inhibition of VEGFR-1 may be beneficial in AMD where macrophage infiltration has been suggested to play a role in the etiology of the disease. VEGF produced by hypoxic retinal pigmented epithelial cells has been postulated to act as a chemotactic factor for macrophages, which can then secrete additional VEGF as well as other proangiogenic factors.
We have identified and characterized a novel small molecule inhibitor of VEGFR-2, SU10944. This compound is a potent, ATP-competitive inhibitor of VEGFR-2 biochemical activity and is active in the nanomolar range in cellular assays. SU10944 can be administered in vivo by the oral route and achieves sufficient exposure to inhibit nearly all VEGF-stimulated neovascularization and vascular permeability. A selective, well tolerated VEGFR inhibitor, administered orally or by local delivery, should be of therapeutic benefit in both diabetic retinopathy and exudative age-related macular degeneration. In addition, we believe compounds of this nature will be valuable in delineating the role of VEGF in various forms of pathological angiogenesis where multiple kinases may play contributing roles. Clinical trials will be necessary to show the potential prophylactic or therapeutic utility of these novel and selective VEGFR inhibitors in human eye diseases. The discovery of a multiple VEGFR inhibitors representing a variety of pharmacophores offers the opportunity to generate new molecules with increased potency or improved pharmaceutical properties by rational design based on cocrystals with VEGFR-2.
